ahlam1399
03-11-2016, 12:39 AM
FDA sets new date for panel review of Sarepta?s muscle drug
(Reuters) - An independent panel of experts to the U.S. Food and Drug Administration (FDA) will discuss Sarepta Therapeutics Inc's muscle wasting drug on April 25, nearly three months after the original date.
http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/a2.img (http://da.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/ach.img (http://adchoice.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/ach.htm)http://pi.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/a2t.imghttp://pi2.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e2cd07a/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=ljAAZd2-GKc:JYoa-EpaTbw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=ljAAZd2-GKc:JYoa-EpaTbw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=ljAAZd2-GKc:JYoa-EpaTbw:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=ljAAZd2-GKc:JYoa-EpaTbw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=ljAAZd2-GKc:JYoa-EpaTbw:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/ljAAZd2-GKc
(Reuters) - An independent panel of experts to the U.S. Food and Drug Administration (FDA) will discuss Sarepta Therapeutics Inc's muscle wasting drug on April 25, nearly three months after the original date.
http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/a2.img (http://da.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/ach.img (http://adchoice.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/ach.htm)http://pi.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/a2t.imghttp://pi2.feedsportal.com/r/247394257659/u/49/f/654207/c/35217/s/4e2cd07a/sc/14/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e2cd07a/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=ljAAZd2-GKc:JYoa-EpaTbw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=ljAAZd2-GKc:JYoa-EpaTbw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=ljAAZd2-GKc:JYoa-EpaTbw:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=ljAAZd2-GKc:JYoa-EpaTbw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=ljAAZd2-GKc:JYoa-EpaTbw:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/ljAAZd2-GKc